Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT07282041
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 130 participants
- Registry
-
NCT07282041
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Singapore
- Registry status
- Recruiting
Technical summary
Registry record NCT07282041. Randomized; single masking; primary purpose prevention. Start 2025-12-17 (actual); primary completion 2030-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
- Acronym
- RADIANT
- Condition
- Intracranial Atherosclerosis
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- National University of Singapore
Record details
- Record id
cardio:ct-nct07282041- Content hash
6d2ea1de88b84e2609853f5fc30e55e786bd453e265e59114c478ac8522c847c